Surrozen, Inc./DE
Close on Oct 19, 2026
- Market cap
- $551.80M
- P/E (TTM)
- –
- Dividend yield
- –
About Surrozen
Biological Products, (No Diagnostic Substances), SIC 2836
Surrozen is a biotechnology company that discovers and develops antibody-based therapeutics designed to selectively regulate the Wnt signaling pathway for tissue repair. Its operations center on ophthalmology, targeting diseases such as diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema. The company's lead candidates include SZN-8141, SZN-8143, and SZN-413, which aim to restore retinal vascular integrity and inhibit abnormal blood vessel growth. It also conducts preclinical research programs for corneal endothelial injuries and photoreceptor degeneration. Its therapies target patients suffering from serious ocular disorders, and its clients include corporate partners such as Boehringer Ingelheim International GmbH.
Surrozen is located in South San Francisco, California. The company has investigated the biological role of Wnt signaling across more than twenty different tissue types, maintaining a focused pipeline of preclinical ophthalmic programs and entering strategic development agreements with international corporate collaborators.
Summary of the business section of Surrozen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Surrozen, Inc./DE
- Headquarters
- South San Francisco, CA
- Address
- 171 Oyster Point Blvd, Suite 400 94080
- Phone
- (650) 475-2820
- Website
- surrozen.com
- Employees
- 44, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Francisco, California
Stock & identifiers
- Ticker
- SRZN
- Exchange
- Nasdaq
- IPO date
- Nov 19, 2020
- Shares outstanding
- 12M, Aug 4, 2026
- Public float
- $59.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Apr 10, 2024; 1-for-15 reverse, Dec 14, 2023
- SEC CIK
- 1824893
- CUSIP
- 86889P208
- ISIN
- US86889P2083
- EIN
- 30-1374889
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Craig C. Parker | Chief Executive Officer, Director | 18,175 |
| Andrew Pedrum Maleki | Chief Financial Officer | 607 |
| Charles O. Williams | Chief Operating Officer | 18,237 |
| Yang Li | Exec. Vice President, Research | 19,584 |
| Tim Kutzkey | Director | 2,261,777 |
| Mary Haak-Frendscho | Director | 35,129 |
| Christopher Y. Chai | Director | 35,129 |
| Eric Bjerkholt | Director | – |
| Anna Berkenblit | Director | 35,129 |
| David J. Woodhouse | Director | 35,129 |
| Mace Rothenberg | Director | 35,129 |
| Shao-Lee Lin | Director | 35,129 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Craig Parker | $2.82M | $4.81M | $1.40M | $240 | – |
| FY2024 Craig Parker | $1.52M | $1.93M | $927.26K | $153 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had 44 full-time employees, with 27 in research and development and 17 in general and administrative functions.”
Corporate history
Events identified from SEC filings